A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma (STREAM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01377025|
Recruitment Status : Unknown
Verified December 2014 by Prof. Dr. med. Max. E. Scheulen, University Hospital, Essen.
Recruitment status was: Active, not recruiting
First Posted : June 20, 2011
Last Update Posted : December 3, 2014
Uveal melanoma is the most common primary intra-ocular malignancy in adults with an incidence of 0.6 - 0.7 per 100,000 per year.
Prognosis of metastatic uveal melanoma is poor. In retrospective analyses a median survival time after detection of metastases of 5 months (Flaherty et al, 1998) and 7 months (Kath et al, 1993) was reported. For patients receiving no treatment reported median survival was 2.0 months compared with 5.2 months for those receiving treatment for metastases (Gragoudas et al, 1991).
Up to now there is no established treatment of metastatic uveal melanoma. Some therapeutic approaches with locoregional treatment or systemic chemotherapy have been undertaken:
In case of metastatic disease which is confined to the liver in about 85% of patients with uveal melanoma surgical resection led to a median survival of 14 months (Mariani et al, 2009) or 19 months and a 5-year survival rate of 22% in a selected patient population (Adam et al, 2006).
As locoregional treatment option treatment with fotemustine via direct intra-arterial hepatic infusion was investigated and led to a median survival of 15 months (Peters et al, 2006). This was not a randomized trial, but a report on 101 consecutive treated patients. Additional debulking surgery was performed whenever feasible.
A randomized phase III trial comparing intra-arterial hepatic fotemustine administration with intravenous systemic fotemustine and overall survival as primary endpoint is still ongoing (EORTC 18021).
Thus, no systemic chemotherapy is approved for metastatic uveal melanoma. Although no specific genes have been linked to the pathogenesis of uveal melanoma, preclinical studies suggest potential benefit of inhibitors of Bcl-2, ubiquitin-proteasome, histone deactylase, mitogen-activated protein kinase and phosphatidylinositol-3-kinase-AKT pathways, and receptor tyrosine kinases.
Thus, sorafenib as inhibitor of b-Raf and Raf-1 (c-Raf or c-Raf-1), pro-angiogenic vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR) may potentially lead to a benefit for patients with metastatic uveal melanoma in terms of disease control and prolongation of survival.
|Condition or disease||Intervention/treatment||Phase|
|Uveal Melanoma||Drug: Placebo Drug: Sorafenib||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma|
|Study Start Date :||June 2011|
|Estimated Primary Completion Date :||June 2016|
|Estimated Study Completion Date :||June 2017|
Experimental: Sorafenib blinded Phase
400 mg Sorafenib bid until PD
400 mg Sorafenib bid until PD if staging after Run-In was SD
Placebo Comparator: Placebo blinded Phase
Two tbl. in the morning and two tbl. in teh evening until PD
two tablets in the morning and two in the evening.
Experimental: Sorafenib Open Phase
400 mg Sorafenib bid until PD
400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
- Progression Free Survival [ Time Frame: Every 8 weeks for 1 year ]
- Number of patients with adverse events [ Time Frame: Every 8 weeks for 1 year ]
- Overall Survival [ Time Frame: Every 8 weeks for 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01377025
|Universitätsmedizin Berlin, Charité Campus Benjamin Franklin|
|Berlin, Germany, 12203|
|Erlangen, Germany, 91052|
|Essen, Germany, 45147|
|Principal Investigator:||Max E. Scheulen, Prof.||Universiätsklinikum Essen|